Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

iZafe Group

BST:M02
Snowflake Description

High growth potential with imperfect balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
M02
BST
SEK50M
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

iZafe Group AB (publ), a medical technology company, researches, develops, and markets medical products for medication and drug management in Sweden and internationally. The last earnings update was 40 days ago. More info.


Add to Portfolio Compare Print
  • iZafe Group has significant price volatility in the past 3 months.
M02 Share Price and Events
7 Day Returns
4%
BST:M02
4.1%
DE Healthcare Services
7.3%
DE Market
1 Year Returns
-68.1%
BST:M02
0.9%
DE Healthcare Services
-17.7%
DE Market
M02 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
iZafe Group (M02) 4% -24.2% -31.2% -68.1% - -
DE Healthcare Services 4.1% -8.3% -18.1% 0.9% 24.9% 85.3%
DE Market 7.3% -17.9% -25.8% -17.7% -25.6% -29%
1 Year Return vs Industry and Market
  • M02 underperformed the Healthcare Services industry which returned 0.9% over the past year.
  • M02 underperformed the Market in Germany which returned -17.7% over the past year.
Price Volatility
M02
Industry
5yr Volatility vs Market

Value

 Is iZafe Group undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for iZafe Group. This is due to cash flow or dividend data being unavailable. The share price is €0.1472.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for iZafe Group's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are iZafe Group's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BST:M02 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in SEK SEK-1.16
OM:IZAFE B Share Price ** OM (2020-03-30) in SEK SEK1.71
Germany Healthcare Services Industry PE Ratio Median Figure of 6 Publicly-Listed Healthcare Services Companies 11.1x
Germany Market PE Ratio Median Figure of 400 Publicly-Listed Companies 16.36x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of iZafe Group.

BST:M02 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:IZAFE B Share Price ÷ EPS (both in SEK)

= 1.71 ÷ -1.16

-1.47x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • iZafe Group is loss making, we can't compare its value to the DE Healthcare Services industry average.
  • iZafe Group is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does iZafe Group's expected growth come at a high price?
Raw Data
BST:M02 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.47x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
97.2%per year
Europe Healthcare Services Industry PEG Ratio Median Figure of 14 Publicly-Listed Healthcare Services Companies 2.29x
Germany Market PEG Ratio Median Figure of 254 Publicly-Listed Companies 1.2x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for iZafe Group, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on iZafe Group's assets?
Raw Data
BST:M02 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in SEK SEK1.28
OM:IZAFE B Share Price * OM (2020-03-30) in SEK SEK1.71
Germany Healthcare Services Industry PB Ratio Median Figure of 7 Publicly-Listed Healthcare Services Companies 2.88x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.43x
BST:M02 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:IZAFE B Share Price ÷ Book Value per Share (both in SEK)

= 1.71 ÷ 1.28

1.34x

* Primary Listing of iZafe Group.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • iZafe Group is good value based on assets compared to the DE Healthcare Services industry average.
X
Value checks
We assess iZafe Group's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check)
  5. iZafe Group has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is iZafe Group expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
97.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is iZafe Group expected to grow at an attractive rate?
  • iZafe Group's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • iZafe Group's earnings growth is expected to exceed the Germany market average.
  • iZafe Group's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
BST:M02 Future Growth Rates Data Sources
Data Point Source Value (per year)
BST:M02 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 97.2%
BST:M02 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 38.2%
Europe Healthcare Services Industry Earnings Growth Rate Market Cap Weighted Average 28.6%
Europe Healthcare Services Industry Revenue Growth Rate Market Cap Weighted Average 8.5%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.3%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BST:M02 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BST:M02 Future Estimates Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 49 10 7 1
2021-12-31 35 4 0 1
2020-12-31 23 -11 -12 1
BST:M02 Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2019-12-31 14 -15 -23
2019-09-30 15 -20 -18
2019-06-30 14 -15 -16
2019-03-31 11 -2 -14
2018-12-31 8 -1 -11
2018-09-30 3 -3 -11
2018-06-30 1 -4 -10
2018-03-31 1 -5 -7
2017-12-31 1 -4 -4
2017-09-30 0 -6 -2
2017-06-30 0 -5 -2
2017-03-31 0 -6

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • iZafe Group's earnings are expected to grow significantly at over 20% yearly.
  • iZafe Group's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BST:M02 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from iZafe Group Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:M02 Future Estimates Data
Date (Data in SEK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31 0.22 0.22 0.22 1.00
2021-12-31 0.01 0.01 0.01 1.00
2020-12-31 -0.38 -0.38 -0.38 1.00
BST:M02 Past Financials Data
Date (Data in SEK Millions) EPS *
2019-12-31 -1.16
2019-09-30 -1.08
2019-06-30 -1.07
2019-03-31 -0.99
2018-12-31 -0.87
2018-09-30 -0.85
2018-06-30 -0.81
2018-03-31 -0.56
2017-12-31 -0.38
2017-09-30 -0.19
2017-06-30 -0.17
2017-03-31 -0.55

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • iZafe Group is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess iZafe Group's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
iZafe Group has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has iZafe Group performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare iZafe Group's growth in the last year to its industry (Healthcare Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • iZafe Group does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare iZafe Group's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare iZafe Group's 1-year growth to the DE Healthcare Services industry average as it is not currently profitable.
Earnings and Revenue History
iZafe Group's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from iZafe Group Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:M02 Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 14.33 -23.12 12.87
2019-09-30 14.72 -18.06 13.25
2019-06-30 14.08 -16.03 12.90
2019-03-31 10.91 -13.69 10.02
2018-12-31 7.57 -11.31 7.39
2018-09-30 3.35 -10.81 3.97
2018-06-30 0.65 -9.81 1.89
2018-03-31 0.65 -6.50 1.50
2017-12-31 0.66 -4.27 1.11
2017-09-30 0.01 -2.30 0.66
2017-06-30 0.01 -2.05 0.36
2017-03-31 0.00 -6.18 0.20
2016-12-31 -6.36 0.05
2016-09-30 -7.11 0.14
2016-06-30 -6.90 0.27
2016-03-31 -2.61 0.41
2015-12-31 -2.60 0.54
2015-09-30 -2.90 1.51
2015-06-30 -2.98 0.90
2015-03-31 -3.05 1.25
2014-12-31 -3.17 1.12
2014-09-30 0.00 -6.92 0.01
2014-06-30 0.00 -6.63 0.65
2014-03-31 0.00 -3.75 0.32
2013-12-31 0.01 -7.23 0.45
2013-09-30 0.01 -3.58 0.68
2013-06-30 0.02 -3.66 0.60

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if iZafe Group has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if iZafe Group has efficiently used its assets last year compared to the DE Healthcare Services industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if iZafe Group improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess iZafe Group's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
iZafe Group has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is iZafe Group's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up iZafe Group's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • iZafe Group's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • iZafe Group's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of iZafe Group's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from iZafe Group Company Filings, last reported 3 months ago.

BST:M02 Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 36.89 10.20 7.47
2019-09-30 28.10 7.09 0.01
2019-06-30 24.42 10.09 0.46
2019-03-31 11.72 9.85 0.22
2018-12-31 10.12 20.98 1.21
2018-09-30 6.68 8.57 0.35
2018-06-30 4.42 3.25 0.35
2018-03-31 8.25 0.63 0.14
2017-12-31 11.19 0.71 3.58
2017-09-30 8.11 0.78 1.43
2017-06-30 8.79 0.83 2.84
2017-03-31 5.42 0.90 1.25
2016-12-31 5.42 0.98 3.56
2016-09-30
2016-06-30 4.43 1.10 0.22
2016-03-31 8.72 1.28 0.11
2015-12-31 8.72 1.28 0.11
2015-09-30 8.72 1.28 0.11
2015-06-30 9.67 1.45 0.37
2015-03-31 9.67 1.45 0.37
2014-12-31 9.04 1.92 0.27
2014-09-30 9.68 1.92 0.34
2014-06-30 10.17 1.81 0.26
2014-03-31 14.41 1.35 0.05
2013-12-31 11.69 1.39 0.08
2013-09-30 16.37 1.22 0.05
2013-06-30 17.21 1.00 0.05
  • iZafe Group's level of debt (27.4%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (21.2% vs 27.4% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • iZafe Group has less than a year of cash runway based on current free cash flow.
  • iZafe Group has less than a year of cash runway if free cash flow continues to grow at historical rates of 39.3% each year.
X
Financial health checks
We assess iZafe Group's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. iZafe Group has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is iZafe Group's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from iZafe Group dividends.
If you bought €2,000 of iZafe Group shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate iZafe Group's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate iZafe Group's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BST:M02 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Healthcare Services Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 1.7%
Germany Market Average Dividend Yield Market Cap Weighted Average of 323 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 1%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BST:M02 Future Dividends Estimate Data
Date (Data in SEK) Dividend per Share (annual) Avg. No. Analysts
2022-12-31
2021-12-31
2020-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as iZafe Group has not reported any payouts.
  • Unable to verify if iZafe Group's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of iZafe Group's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as iZafe Group has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess iZafe Group's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can iZafe Group afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. iZafe Group has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of iZafe Group's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Anders Segerström
AGE 34
TENURE AS CEO 1.2 years
CEO Bio

Mr. Anders Segerström serves as the CEO at MediRätt AB (publ) since 2019. Mr. Segerström has been in leading company roles in the fields of business development, sales and management since 2005. In 2017, Anders Segerström became CEO of Sensec Personlig Säkerhet, which he grew into a profitable company that was acquired by MediRätt before changing name to iZafe. Previously, Anders was head of business development at the same company, and before then head of sales at the broadband provider Net1. Mr. Segerström has a degree in Business Management from the IHM Business School.

CEO Compensation
  • Insufficient data for Anders to compare compensation growth.
  • Insufficient data for Anders to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the iZafe Group management team in years:

1.2
Average Tenure
53
Average Age
  • The average tenure for the iZafe Group management team is less than 2 years, this suggests a new team.
Management Team

Anders Segerström

TITLE
Chief Executive Officer
AGE
34
TENURE
1.2 yrs

Barbro Sjönell

TITLE
Co-Founder

Mikael Svensson

TITLE
Chief Operating Officer
AGE
53
TENURE
3.2 yrs

Göran Hermanson

TITLE
Chief Operating Officer
AGE
66
TENURE
1.2 yrs

Tobias Johansson

TITLE
Head of Sales & VP
TENURE
1.2 yrs
Board of Directors Tenure

Average tenure and age of the iZafe Group board of directors in years:

5.5
Average Tenure
44
Average Age
  • The tenure for the iZafe Group board of directors is about average.
Board of Directors

Carl Merner

TITLE
Chairman of the Board
AGE
44
TENURE
1.2 yrs

Barbro Sjönell

TITLE
Co-Founder

Göran Sjönell

TITLE
Director
TENURE
11.3 yrs

Viveca Gyberg

TITLE
Director
AGE
36
TENURE
2.2 yrs

Carl Sjönell

TITLE
Director
AGE
48
TENURE
8.8 yrs

Calle Sjönell

TITLE
Director
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
13. Nov 19 Buy Carl Merner Individual 13. Nov 19 13. Nov 19 21,000 €0.23 €4,902
12. Nov 19 Buy Carl Merner Individual 08. Nov 19 08. Nov 19 20,000 €0.24 €4,860
11. Sep 19 Buy Carl Merner Individual 10. Sep 19 10. Sep 19 2,000 €0.31 €616
02. Oct 19 Buy Carl Merner Individual 02. Oct 19 02. Oct 19 20,000 €0.37 €7,401
01. Oct 19 Buy Carl Merner Individual 01. Oct 19 01. Oct 19 10,000 €0.38 €3,794
10. Sep 19 Buy Carl Merner Individual 10. Sep 19 10. Sep 19 10,000 €0.31 €3,063
12. Jun 19 Buy Carl Merner Individual 11. Jun 19 11. Jun 19 30,000 €0.42 €12,633
10. Jun 19 Buy Carl Merner Individual 07. Jun 19 07. Jun 19 13,500 €0.42 €5,667
23. May 19 Buy Carl Merner Individual 21. May 19 21. May 19 385,135 €0.48 €185,018
16. May 19 Buy Carl Merner Individual 15. May 19 15. May 19 28,500 €0.42 €11,903
08. May 19 Buy Carl Merner Individual 08. May 19 08. May 19 50,000 €0.51 €25,603
03. Apr 19 Buy Carl Merner Individual 02. Apr 19 02. Apr 19 8,000 €0.48 €3,830
01. Apr 19 Buy Carl Merner Individual 01. Apr 19 01. Apr 19 10,000 €0.49 €4,901
X
Management checks
We assess iZafe Group's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. iZafe Group has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

iZafe Group AB (publ), a medical technology company, researches, develops, and markets medical products for medication and drug management in Sweden and internationally. The company offers Dosell, a drug dispenser for homecare that reminds patients when to take medication and triggers an alarm if a patient fails to do so. It also provides MediKoll, an app that offers patients information about side effects, reactions, and allergies related to various types of medication. The company offers its products for the pharmaceutical, hospital and care home, and pharmacy and private healthcare markets. The company was formerly known as MediRätt AB (publ) and changed its name to iZafe Group AB (publ) in May 2019. iZafe Group AB (publ) was founded in 2008 and is based in Lidingö, Sweden.

Details
Name: iZafe Group AB (publ)
M02
Exchange: BST
Founded: 2008
SEK4,484,003
28,928,187
Website: http://www.izafe.se
Address: iZafe Group AB (publ)
Stockholmsvägen 33,
Lidingö,
Stockholm County, 181 33,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM IZAFE B Class B Shares OMX Nordic Exchange Stockholm SE SEK 04. Apr 2011
BST M02 Class B Shares Boerse-Stuttgart DE EUR 04. Apr 2011
Number of employees
Current staff
Staff numbers
0
iZafe Group employees.
Industry
Health Care Technology
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/31 00:02
End of day share price update: 2020/03/30 00:00
Last estimates confirmation: 2020/02/24
Last earnings filing: 2020/02/20
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.